Pharmaceutical companies supplying products under the UK’s freshly-launched antibiotics subscription model must now certify compliance with a new industry standard.
The “BSI Kitemark for Minimized Risk of Antimicrobial Resistance (AMR)” aims to ensure responsible antibiotic manufacturing and reduce the environmental impact that contributes to the growing AMR crisis.
The move aligns with the 2024-2029 UK National AMR Action Plan, which emphasizes stringent controls on antibiotic production.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze